Get started Log in

MNOV — Medicinova Share News

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Market Cap
$68.66m
Enterprise Value
$43.24m
Revenue
$0.41m

Brief: Medicinova Receives Gene Therapy Milestone Payment
05/10/2023 24:01
Brief: Medicinova Announces Results Of Studies Under BARDA Contract To Develop MN 166 (Ibudilast)
28/09/2023 24:06
Brief: Medicinova Inc - Receives Notice Of Intention To Grant For A New Patent Covering Mn-166 (Ibudilast) For The Treatment Of Macular Injury In Europe
17/08/2023 24:02
MediciNova Inc expected to post a loss of 8 cents a share - Earnings Preview
09/08/2023 03:05
MediciNova Inc expected to post a loss of 8 cents a share - Earnings Preview
09/05/2023 03:04
Brief: Medicinova Announces Additional Extension Of Barda Contract To Develop Mn-166 (Ibudilast) As A Medical Countermeasure Against Chlorine Gas-Induced Lung Injury
09/03/2023 23:05
MediciNova Inc expected to post a loss of 8 cents a share - Earnings Preview
10/02/2023 22:30
Brief: Medicinova Announces Health Canada Grants Authorization To Commence Multi-arm Phase 2/3 Clinical Trial To Evaluate MN-166 (ibudilast) In Long COVID
08/02/2023 23:38
Brief: Medicinova Announces Completion Of Enrollment In The Mid-Stage Clinical Trial Of Alcohol Use Disorder Drug
30/01/2023 23:28
Brief: Medicinova Announces Completion Of Enrollment In The Phase 2 Clinical Trial Evaluating Mn-166 (Ibudilast)
13/01/2023 24:12
Brief: Medicinova Receives Notice Of Allowance For New Patent In Brazil
10/01/2023 03:00
Brief: Medicinova Announces Additional Positive Results About Effects Of MN-001 On Serum Lipid Panel In Type 2 Diabetes And NAFLD Patients Presented At IDF 2022 Congress
06/12/2022 23:03
Brief: MediciNova Announces Positive Results From Secondary Analysis Of Phase 2 Trial Of MN-166 Published In The American Journal Of Drug And Alcohol Abuse
05/12/2022 23:13
MediciNova Inc reports results for the quarter ended in September - Earnings Summary
11/11/2022 03:57
MediciNova Inc expected to post a loss of 9 cents a share - Earnings Preview
08/11/2022 17:41
Brief: Medicinova Receives Issue Notification For A New Patent Covering MN-166 (Ibudilast) For Treatment Of Glioblastoma
15/09/2022 24:02
Brief: Medicinova: Received Notice Of Allowance For New Patent Covering Mn-001 And Mn-002 For Treatment Of Hypertriglyceridemia, Hypercholesterolemia, And Hyperlipoproteinemia In Canada
14/09/2022 24:11
Brief: MediciNova Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
26/08/2022 21:14
Brief: Medicinova Reaches Agreement To Participate In Grant-Funded Clinical Trial To Evaluate Mn-166 (Ibudilast) For The Treatment Of Long Covid
16/08/2022 11:50
MediciNova Inc expected to post a loss of 9 cents a share - Earnings Preview
09/08/2022 03:04